Differential Protein Expression between Cystic and Solid Vestibular Schwannoma Using Tandem Mass Tag‐Based Quantitative Proteomic Analysis

Xu, Jiawei; Ma, Jing; Shi, Yuxuan; Yin, Dongming; Zhang, Yang; Dai, Peidong; Zhang, Weidong; Zhang, Tianyu

doi:10.1002/prca.201900112

Cited by 7 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMP-2 and its endogenous inhibitors tissue inhibitors of metalloproteinase (TIMP)-1 were found interstitially in sporadic solid VS, while the majority of MMP-9 was localized in tumor cells, and its concentration in tumor sample homogenates was positively correlated with the absolute tumor growth rate ( 40 ). Consistent with previous studies showing that the proteolytic activity of MMPs might degrade collagen, fibronectin, laminin and contribute to cyst formation and expansion, the expression of MMP-2 and MMP-9 were upregulated in cystic VS samples compared with solid VS ( 147 ). In cystic VS tissues, MMP-2 was localized to tumor cells on the cyst cavity inner surface and its levels were higher in the cystic fluid than in other samples ( 148 ).…”

Section: Resultssupporting

confidence: 91%

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

et al. 2021

View full text Add to dashboard Cite

Vestibular schwannomas (VSs, also known as acoustic neuromas) are relatively rare benign brain tumors stem from the Schwann cells of the eighth cranial nerve. Tumor growth is the paramount factor for neurosurgeons to decide whether to choose aggressive treatment approach or careful follow-up with regular magnetic resonance imaging (MRI), as surgery and radiation can introduce significant trauma and affect neurological function, while tumor enlargement during long-term follow-up will compress the adjacent nerves and tissues, causing progressive hearing loss, tinnitus and vertigo. Recently, with the deepening research of VS biology, some proteins that regulate merlin conformation changes, inflammatory cytokines, miRNAs, tissue proteins and cerebrospinal fluid (CSF) components have been proposed to be closely related to tumor volume increase. In this review, we discuss advances in the study of biomarkers that associated with VS growth, providing a reference for exploring the growth course of VS and determining the optimal treatment strategy for each patient.

show abstract

Section: Resultssupporting

confidence: 91%

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

et al. 2021

View full text Add to dashboard Cite

show abstract

“…COL1A1 and COL1A2 proteins were recognised as potential indicators for diagnosing and treating CVS. This suggested that reduced collagen deposition could be one of the reasons why CVS patients are vulnerable to bleeding [ 77 ].…”

Section: Investigating Inner Ear Diseases Through Proteomics and Meta...mentioning

confidence: 99%

The Current State of Proteomics and Metabolomics for Inner Ear Health and Disease

Khorrami,

Pastras,

Haynes

et al. 2024

Proteomes

View full text Add to dashboard Cite

Characterising inner ear disorders represents a significant challenge due to a lack of reliable experimental procedures and identified biomarkers. It is also difficult to access the complex microenvironments of the inner ear and investigate specific pathological indicators through conventional techniques. Omics technologies have the potential to play a vital role in revolutionising the diagnosis of ear disorders by providing a comprehensive understanding of biological systems at various molecular levels. These approaches reveal valuable information about biomolecular signatures within the cochlear tissue or fluids such as the perilymphatic and endolymphatic fluid. Proteomics identifies changes in protein abundance, while metabolomics explores metabolic products and pathways, aiding the characterisation and early diagnosis of diseases. Although there are different methods for identifying and quantifying biomolecules, mass spectrometry, as part of proteomics and metabolomics analysis, could be utilised as an effective instrument for understanding different inner ear disorders. This study aims to review the literature on the application of proteomic and metabolomic approaches by specifically focusing on Meniere’s disease, ototoxicity, noise-induced hearing loss, and vestibular schwannoma. Determining potential protein and metabolite biomarkers may be helpful for the diagnosis and treatment of inner ear problems.

show abstract

“…Cystic VSs also express elevated levels of MMP-2 and MMP-9 compared to solid tumors. 47 In addition, MMP-14 is also upregulated in VSs, and its proteolytic activity correlates with sensorineural hearing loss and poor surgical outcomes. 48 ADAM9, a membrane-anchored ECM modulating protein, is associated with an aggressive tumor state and poor prognosis in cancer.…”

Section: Molecular Basis Of Vssmentioning

confidence: 99%

From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas

Guo,

Zheng,

Chen

et al. 2024

Neuro-Oncology Advances

View full text Add to dashboard Cite

Vestibular schwannomas are rare intracranial tumors originating from Schwann cells of the vestibular nerve. Despite their benign nature, these tumors can exert significant mass effects and debilitating symptoms, including gradual hearing loss, vertigo, facial nerve dysfunction, and headaches. Current clinical management options encompass watch-and-scan, surgery, radiation therapy, and off-label medication. However, each approach exhibits its own challenges and harbors limitations that underscore the urgent need for therapeutic treatments. Over the last two decades, extensive elucidation of the molecular underpinnings of vestibular schwannomas has unraveled genetic anomalies, dysregulated signaling pathways downstream of receptor tyrosine kinases, disrupted extracellular matrix, inflammatory tumor microenvironment, and altered cerebrospinal fluid composition as integral factors in driving the development and progression of the disease. Armed with this knowledge, novel therapeutic interventions tailored to the unique molecular characteristics of those conditions are actively being pursued. This review underscores the urgency of addressing the dearth of Food and Drug Administration (FDA)-approved drugs for vestibular schwannoma, highlighting the key molecular discoveries and their potential translation into therapeutics. It provides an in-depth exploration of the evolving landscape of therapeutic development, which is currently advancing from bench to bedside. These ongoing efforts hold the promise of significantly transforming the lives of vestibular schwannoma patients in the future.

show abstract

Differential Protein Expression between Cystic and Solid Vestibular Schwannoma Using Tandem Mass Tag‐Based Quantitative Proteomic Analysis

Cited by 7 publications

References 36 publications

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

The Current State of Proteomics and Metabolomics for Inner Ear Health and Disease

From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas

Contact Info

Product

Resources

About